Top

Published in:

01-03-2008 | Review

Mineral and bone disorder after renal transplantation: a review

Authors: Hazim Sadideen, Adrian Covic, David Goldsmith

Published in: International Urology and Nephrology | Issue 1/2008

Abstract

Chronic kidney disease–mineral bone disorder is a common clinical picture encountered in patients with end-stage renal disease and is the result of additive pathophysiological processes. Renal transplantation remains the treatment of choice for these patients, especially as advances in this field have allowed for enhanced allograft survival. However, with increasing success of renal transplantation has come a greater appreciation of some of its subsequent complications, such as posttransplantation bone disease. Recently, persistent hyperparathyroidism and osteopenia–osteoporosis have been given specific attention. Traditionally, persistent hyperparathyroidism has been treated with parathyroidectomy, although the role that calcimimetics may play in the future is promising. Newer aspects to medical management of osteopenia–osteoporosis, such as the efficacy of bisphosphonate therapy and early steroid withdrawal, are becoming apparent and some of the newer drugs for the treatment of osteoporosis are yet to be investigated in this subgroup of patients.

Weisinger JR, Carlini RG, Rojas E (2006) Bone disease after renal transplantation. Clin J Am Soc Nephrol 1:1300–1313PubMedCrossRef

Martin et al (2001) The parathyroids in renal disease. In: Bilezikian JP, Marcus R, Levine MA (eds) The parathyroids: basic and clinical concepts, 2nd edn. Academic Press, New York, pp 625–634

http://www.roche.com/pages/facets/11/ostedefe.htm

Ferreira A (2006) Development of renal bone disease. Eur J Clin Invest 36(Suppl 2):212 (review)

Moe S, Drueke T, Cunningham J et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving global outcomes (KDIGO). Kidney Int 69(11):1945–1953PubMedCrossRef

Moe SM, Drueke T, Lameire N et al (2007) Chronic kidney disease–mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis 14(1):3–12 (review)PubMedCrossRef

Torres A, Lorenzo V, Salido E (2002) Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 13(2):551–558PubMed

Messa P, Sindici C, Cannella G et al (1998) Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 54:1704–1713PubMedCrossRef

Evenepoel P, Claes K, Kuypers D et al (2004) Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 19:1281–1287PubMedCrossRef

10.

Rix M, Lewin E, Olgaard K (2003) Posttransplant bone disease. Transplant Rev 17(4):176–186CrossRef

11.

Gwinner W, Suppa S, Mengel M, Hoy L, Kreipe HH, Haller H, Schwarz A (2005) Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 5(8):1934–1941PubMedCrossRef

12.

Reinhardt W, Bartelworth H, Jockenhövel F et al (1998) Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 13:436–442PubMedCrossRef

13.

Lobo PI, Cortez MS, Stevenson W et al (1995) Normocalcemic hyperparathyroidism associated with relatively low 1:25 vitamin D levels post-renal transplant can be successfully treated with oral calcitriol. Clin Transplant 9(4):277–281PubMed

14.

Koch Nogueira PC, David L, Cochat P (2000) Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol 14:342–346PubMedCrossRef

15.

Tominaga Y, Kohara S, Namii Y et al (1996) Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 20(7):744–750PubMedCrossRef

16.

Torres A, Rodríguez AP, Concepción MT et al (1998) Parathyroid function in long-term renal transplant patients: importance of pretransplant PTH levels. Nephrol Dial Transplant 13(Suppl 3):94–97PubMedCrossRef

17.

Sommer S, Berndt T, Craig T et al (2007) The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol 103(3–5):497–503PubMedCrossRef

18.

Bhan I, Shah A, Holmes J et al (2006) Post-transplant hypophosphatemia: tertiary ‘Hyper-Phosphatoninism’? Kidney Int 70(8):1486–1494PubMedCrossRef

19.

Evenepoel P, Naesens M, Claes K et al (2007) Tertiary ‘hyperphosphatoninism’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7(5):1193–1200PubMedCrossRef

20.

D’Alessandro AM, M elzer JS, Pirsch JD et al (1989) Tertiary hyperparathyroidism after renal transplantation: operative indications. Surgery 106:1049–1055PubMed

21.

Parfitt AM (1982) Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrol Metab 8:92–112

22.

Lewin E, Olgaard K (2006) Parathyroidectomy vs. calcimimetics for treatment of persistent hyperparathyroidism after kidney transplantation. Nephrol Dial Transplant 21(7):1766–1769PubMedCrossRef

23.

Parfitt AM (2000) Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 12(4):387–403CrossRef

24.

Abugassa S, Nordenström J, Eriksson S et al (1990) Skeletal remineralization after surgery for primary and secondary hyperparathyroidism. Surgery 107:128–133PubMed

25.

Ogg CS (1967) Total parathyroidectomy in treatment of secondary hyperparathyroidism. Br J Med iv:331–334CrossRef

26.

Dawborn JK, Brown DJ, Douglas MC et al (1983) Parathyroidectomy in chronic renal failure. Nephron 33:100–105PubMed

27.

Felts JH, Whitley JE, Anderson LD, Carpenter HM, Bradshaw HH (1995) Medical and surgical treatment of azotemic osteodystrophy. Ann Intern Med 62:1272–1279

28.

Felsenfeld AJ, Harrelson JM, Gutman RA et al (1982) Osteomalacia after parathyroidectomy in patients with uremia. Ann Intern Med 96:34–39PubMed

29.

Ellis HA (1982) Aluminum and osteomalacia after parathyroidectomy. Ann Intern Med 96(4):533–534PubMed

30.

Rothmund M, Wagner PK, Schark C (1991) Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. World J Surg 15(6):745–50PubMedCrossRef

31.

Drueke TB, Zingraff J (1994) The dilemma of parathyroidectomy in chronic renal failure. Curr Opin Nephrol Hypertens 3(4):386–395PubMedCrossRef

32.

Kessler M, Avila JM, Renoult E et al (1991) Reoperation for secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 6(3):176–179PubMed

33.

Gagne ER, Urena P, Leite-Silva S et al (1992) Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 3(4):1008–1017PubMed

34.

Higgins RM, Richardson AJ, Ratcliffe PJ et al (1991) Total parathyroidectomy alone or with autograft for renal hyperparathyroidism? Q J Med 79(288):323–332PubMed

35.

Hampl H, Steinmuller T, Frohling P et al (1999) Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure. Miner Electrolyte Metab 25(3):161–170PubMedCrossRef

36.

Abdelhadi M, Nordenstrom J (1998) Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 83(11):3845–3851PubMedCrossRef

37.

Triponez F, Dosseh D, Hazzan M et al (2005) Subtotal parathyroidectomy with thymectomy for autonomous hyperparathyroidism after renal transplantation. Br J Surg 92(10):1282–1287PubMedCrossRef

38.

Triponez F, Kebebew E, Dosseh D et al (2006) Less-than-subtotal parathyroidectomy increases the risk of persistent/recurrent hyperparathyroidism after parathyroidectomy in tertiary hyperparathyroidism after renal transplantation. Surgery 140(6):990–997 (discussion 997–999)PubMedCrossRef

39.

Gioviale MC, Gambino G, Maione C (2006) Intraoperative parathyroid hormone monitoring during parathyroidectomy for hyperparathyroidism in waiting list and kidney transplant patients. Transplant Proc 38(4):1003–1005PubMedCrossRef

40.

Serra AL, Schwarz AA, Wick FH et al (2005) Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 20(7):1315–1319PubMedCrossRef

41.

Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG (2005) The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 20(7):1311–1314PubMedCrossRef

42.

Serra AL, Savoca R, Huber AR (2007) Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 22(2):577–583PubMedCrossRef

43.

Srinivas TR, Schold JD, Womer KL et al (2006) Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 1:323–326PubMedCrossRef

44.

Szwarc I, Argiles A, Garrigue V et al (2006) Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 82(5):675–680PubMedCrossRef

45.

European best practice guidelines for renal transplantation (2002) Section IV: long-term management of the transplant recipient. IV.8. Bone disease. Nephrol Dial Transplant 17(Suppl 4):43–48

46.

Sperschneider H, Stein G (2003) Bone disease after renal transplantation. Nephrol Dial Transplant 18(5):874–877. ReviewPubMedCrossRef

47.

Heaf JG (2003) Bone disease after renal transplantation. Transplantation 75(3):315–325PubMedCrossRef

48.

Kasiske BL, Vazquez MA, Harmon WE et al for the American Society of Transplantation (2000) Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 11(Suppl 15):S1–S86PubMed

49.

Grotz W, Rump LC, Niessen A et al (1998) Treatment of osteopenia and osteoporosis after kidney tranplantation. Transplantation 66:1004–1008PubMedCrossRef

50.

Hansen MA, Overgaard K, Riis BJ, Christiansen C (1991) Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 303(6808):961–964PubMed

51.

Pichette V, Bonnardeaux A, Prudhomme L et al (1996) Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 28(1):105–114PubMed

52.

Groth WH, Mundinger FA, Rasenack J et al (1995) Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant 10(11):2096–2100

53.

Delmas PD (2001) Osteoporosis in patients with organ transplants: a neglected problem. Lancet 357:325–326PubMedCrossRef

54.

Zisman AL, Sprague SM (2006) Bone disease after kidney transplantation. Adv Chronic Kidney Dis 13(1):35–46PubMedCrossRef

55.

Palmer SC, Strippoli GF, McGregor DO (2005) Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 4:638–649 reviewCrossRef

56.

Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346(9):653–661PubMedCrossRef

57.

Saag KG, Emkey R, Schnitzer TJ (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced osteoporosis intervention study group. N Engl J Med 339(5):292–299PubMedCrossRef

58.

Ali SM, Esteva FJ, Hortobagyi G et al (2001) Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 19(14):3434–3437PubMed

59.

Mitterbauer C, Schwarz C, Haas M et al (2006) Effects of bisphosphonates on bone loss in the first year after renal transplantation—a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 21(8):2275–2281PubMedCrossRef

60.

Nowacka-Cieciura E, Cieciura T, Baczkowska T et al (2006) Bisphosphonates are effective prophylactic of early bone loss after renal transplantation. Transplant Proc 38(1):165–167PubMedCrossRef

61.

Kovac D, Lindic J, Kandus A et al (2000) Prevention of bone loss with alendronate in kidney transplant recipients. Transplantation 70(10):1542–1543PubMed

62.

Haas M, Leko-Mohr Z, Roschger P (2003) Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 63(3):1130–1136PubMedCrossRef

63.

Fan SL, Almond MK, Ball E (2000) Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57(2):684–690PubMed

64.

Coco M, Glicklich D, Faugere MC et al (2003) Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14(10):2669–2676PubMedCrossRef

65.

Grotz W, Nagel C, Poeschel D et al (2001) Effect of ibrandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12:1530–1537PubMed

66.

Grotz W, Rump JA, Niessen A et al (1998) Treatment of bone pain after kidney transplantation. Transplant Proc 30:2114–2116PubMedCrossRef

67.

van den Ham EC, Kooman JP, Christiaans ML et al (2003) The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transpl Int 16(2):82–87PubMedCrossRef

68.

Farmer CK, Hampson G, Abbs IC et al (2006) Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density. Am J Transplant 6(12):2929–2936PubMedCrossRef

69.

Rolla D, Ballanti P, Marsano L et al (2006) Bone disease in long-term renal transplant recipients with severe osteopenia: a cross-sectional study. Transplantation 81(6):915–921PubMedCrossRef

70.

Tournis S, Economopoulos D, Lyritis GP (2006) Strontium ranelate: a novel treatment in postmenopausal osteoporosis. Ann N Y Acad Sci 1092:403–407PubMedCrossRef

71.

Moen MD, Scott LJ (2006) Recombinant full-length parathyroid hormone (1–84). Drugs 66(18):2371–2381 (discussion 2382–2385. Review)PubMedCrossRef

72.

Lewiecki EM (2006) RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 6(10):1041–1050. ReviewPubMedCrossRef

Title: Mineral and bone disorder after renal transplantation: a review
Authors: Hazim Sadideen
Adrian Covic
David Goldsmith
Publication date: 01-03-2008
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 1/2008
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-007-9310-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Epidemiology and treatment delay in testicular cancer patients: a retrospective study

Spinal epidural abscess in an elderly diabetic end stage renal disease patient on continuous ambulatory peritonial dialysis (CAPD)

World Kidney Day

Comparative study of extracorporeal shock wave lithotripsy outcomes for proximal and distal ureteric stones

Hyperphosphatemia and nicotinic acid in peritoneal dialysis patients

Maximal bladder capacity is a positive predictor of response to desmopressin treatment in patients with MS and nocturia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials